State Affairs Office: revise and issue the negative list of market access (2021 version) before the end of the year to carry out the pilot of relaxing market access

IntoCare Zhang Hui: Ingenuity Forges Quality, Continuous Improvement Safeguards Lives

In 2024, nearly all medical enterprises are exploring overseas markets. This trend is driven by an anti-corruption wave within the medical industry, the demand for financing and initial public offerings, as well as challenges such as excess production capacity. Presently, venturing abroad has become an essential developmental path for medical device enterprises. Successfully entering foreign markets is not only a crucial means for the medical industry to achieve a second grow

Kanghong’s Conbercept Receives Marketing Authorization in Guyana

Kanghong Pharmaceutical (康弘药业) said its subsidiary Kanghong Bioscience had received a drug registration certificate from Guyana’s Food and Drug Department for conbercept ophthalmic injection, marketed under the brand name Lumitin (朗沐).

Wantai BioPharm’s Nine-Valent HPV Vaccine Wins First Overseas Approval in Thailand

Wantai BioPharm (万泰生物) announced on Aug. 11 that the nine-valent HPV vaccine developed by its wholly owned subsidiary, Xiamen Innovax Biotech (万泰沧海), has received marketing authorization from Thailand’s Food and Drug Administration. The approval marks the vaccine’s first clearance outside China and an important step in Wantai BioPharm’s international expansion.

Top 10 Market Cap Chinese Medical Device Companies: Champions and Runners-Up

In a recent boom in the Chinese A-share market, the medical device segment has shown a surprising performance, proving its investability and growth potential.

USD 130 Million Series A Financing Fuels Lepu Biotech

Lepu Biotech announced Series A financing of CNY 900 million. Shiyu Capital took the lead in this round. Lepu Biotech has several pipelines for precision treatment and targeted therapy for solid tumors.